Interní Med. 2019; 21(4): 239-247 | DOI: 10.36290/int.2019.037
Ertugliflozin – SGLT2 inhibitor
- Diabetologická a interní ambulance Ostrava
Sodium-glucose transporter 2 inhibitors (SGLT2i) are the most recent therapeutic strategy in the treatment of type2 diabetes mellitus. Ertugliflozin is the new highly selective and reversible SGLT2inhibitor. This cotransporter is responsible for renal reabsorpction of glucose. Due to this mechanism ertugliflozin increases glucose excretion by the kidney, resulting in reduced glycaemia and improved diabetes control with very low risk of hypoglycaemia. This mechanis of action is completely independent of the action of insulin. Ertugliflozin has been aproved by EMA for treatment od diabetes mellitus type 2 in March 2018. Ertugliflozin is aproved for monotherapy and as add-on therapy to oral antidiabetic agents. In this article there is a summary of knowledge about mechanism of action, efficacy and safety of ertugliflozin.
Keywords: SGLT2 inhibition, diabetes mellitus typ 2, ertugliflozin, glycemic control
Published: November 1, 2019 Show citation
References
- Doporučený postup péče o diabetes mellitus 2. typu, Česká diabetologická společnost J. Škrha, T. Pelikánová, M. Kvapil, dostupná z www.diab.cz
- Pajor AM, Wright EM. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem. 1992; 267(6): 3557-3560.
Go to original source... - Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice. J Biol Chem. 2017; 292(13): 5335-5348. Go to original source...
Go to PubMed... - Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3. 2. 1] octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011; 54(8): 2952-2960. Go to original source... Go to PubMed...
- Dash RP, Babu RJ, Srinivas NR. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica. 2016: 1-12. Go to original source... Go to PubMed...
- Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011; 39(9): 1609-1619. Go to original source... Go to PubMed...
- Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445-456. Go to original source... Go to PubMed...
- SPC Steglatro. http://www.ema.europa.eu/docs/cs_CZ/document_library
- Kumar V, Sahasrabudhe V, Matschke K, et al. Lack of a pharmacokinetic interaction between ertugliflozin and sitagliptin or metformin in healthy subjects. Poster presented at: ASCPT 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 12; 2016; San Diego, CA.
- Sahasrabudhe V, Terra SG, Fountaine RJ, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. Poster presented at: EASD 2015 51st European Association for the Study of Diabetes; September 14; 2015; Stockholm, Sweden.
- Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591-598 Go to original source... Go to PubMed...
- Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017; 19(5): 721-728. Go to original source... Go to PubMed...
- Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glycemic control, body weight, blood pressure (BP), and bone mineral density (BMD) in T2DM inadequately controlled with metformin monotherapy: VERTIS MET Trial. Poster presented at: ADA 2017; June 8; 2017; San Diego, CA. Go to original source... Go to PubMed...
- Pratley R, Eldor R, Golm G, et al. Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes inadequately controlled with metformin: the VERTIS FACTORIAL trial. Poster presented at: EASD 2016 52nd European Association for the Study of Diabetes; September 15; 2016; Munich, Germany.
- Pratley R, Raji A, Eldor R, et al. Safety and efficacy of ertugliflozin plus sitagliptin vs. either treatment alone after 52 weeks in subjects with T2DM inadequately controlled on metformin: VERTIS FACTORIAL trial extension. Oral presentation at: ADA 2017; June 9; 2017; San Diego, CA.
- Lauring B, Eldor R, Liu J, et al. Efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus inadequately controlled on the dual combination of metformin and sitagliptin: the VERTIS SITA2 trial. Poster presented at: EASD 2016 52nd European Association for the Study of Diabetes; September 15; 2016; Munich, Germany.
- Liu J, Eldor R, Dagogo-Jack S, et al. Safety and efficacy of ertugliflozin after 52 weeks in subjects with T2DM inadequately controlled on metformin and sitagliptin: results from the extension phase of the VERTIS SITA2 Trial. Oral presentation at: ADA 2017; June 9; 2017; San Diego, CA.
- Lauring B, Miller SS, Krumins T, et al. Safety and efficacy of ertugliflozin in combination with sitagliptin in subjects with T2DM inadequately controlled on diet and exercise: the VERTIS SITA Trial. Poster presented at: ADA 2017; June 8; 2017; San Diego, CA.
- Hollander P, Liu J, Hill J, et al. Safety and efficacy of ertugliflozin compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. Poster presentation at: EASD 2017; Lisbon, Portugal. Go to original source...
- Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther 2018. Go to original source... Go to PubMed...
- Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016; 18(2): 125-134. Go to original source... Go to PubMed...
- Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res. 2015; 12(2): 90-100. Go to original source... Go to PubMed...